Off-Patent Industry Must Become ‘Focal Point’ For Health Systems Post-COVID

Medicines For Europe And IGBA Set Out Policy Priorities At Athens Conference

Lens Focus Light Focal Point
Generics and biosimilars must be a “focal point” for health systems • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Policy & Regulation

More from Generics Bulletin